Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
M. Emmy M. Dolman(Cancer Institute of New South Wales), Jan J. Molenaar(Princess Máxima Center), Kevin Petrie(University of Sunderland), Marli E. Ebus(Amsterdam UMC Location University of Amsterdam), Rolf W. Sparidans(Slotervaartziekenhuis), Albert Hallsworth(Institute of Cancer Research), Carel J.M. van Noesel(Amsterdam University Medical Centers), Rogier Versteeg(Charité - Universitätsmedizin Berlin), Louis Chesler(Institute of Cancer Research), Evon Poon(Institute of Cancer Research), Yann Jamin(Institute of Cancer Research), Simon P. Robinson(Institute of Cancer Research), Robbert J. Kok(Utrecht University), Huib N. Caron(Emma Kinderziekenhuis), Ilona J.M. den Hartog(Amsterdam UMC Location University of Amsterdam)
Cited by 69
Related Papers
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Neuroblastoma is composed of two super-enhancer-associated differentiation states
|Nature Genetics|2017|566
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461